SG11201901468SA - Antibodies with reduced binding to process impurities - Google Patents
Antibodies with reduced binding to process impuritiesInfo
- Publication number
- SG11201901468SA SG11201901468SA SG11201901468SA SG11201901468SA SG11201901468SA SG 11201901468S A SG11201901468S A SG 11201901468SA SG 11201901468S A SG11201901468S A SG 11201901468SA SG 11201901468S A SG11201901468S A SG 11201901468SA SG 11201901468S A SG11201901468S A SG 11201901468SA
- Authority
- SG
- Singapore
- Prior art keywords
- glaxosmithkline
- road
- international
- antibodies
- hertfordshire
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Information Retrieval, Db Structures And Fs Structures Therefor (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662404849P | 2016-10-06 | 2016-10-06 | |
| PCT/EP2017/075038 WO2018065389A1 (en) | 2016-10-06 | 2017-10-03 | Antibodies with reduced binding to process impurities |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201901468SA true SG11201901468SA (en) | 2019-03-28 |
Family
ID=60143674
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201901468SA SG11201901468SA (en) | 2016-10-06 | 2017-10-03 | Antibodies with reduced binding to process impurities |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11254753B2 (zh) |
| EP (1) | EP3523329A1 (zh) |
| JP (1) | JP7471819B2 (zh) |
| KR (1) | KR20190057083A (zh) |
| CN (1) | CN109790216A (zh) |
| AU (1) | AU2017338291A1 (zh) |
| BR (1) | BR112019004938A2 (zh) |
| CA (1) | CA3037264A1 (zh) |
| IL (1) | IL265748A (zh) |
| MX (1) | MX2019003890A (zh) |
| RU (1) | RU2771330C2 (zh) |
| SG (1) | SG11201901468SA (zh) |
| TW (1) | TW201829453A (zh) |
| WO (1) | WO2018065389A1 (zh) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3630831B1 (en) | 2017-05-25 | 2022-06-15 | Bristol-Myers Squibb Company | Antagonistic cd40 monoclonal antibodies and uses thereof |
| AR117091A1 (es) | 2018-11-19 | 2021-07-07 | Bristol Myers Squibb Co | Anticuerpos monoclonales antagonistas contra cd40 y sus usos |
| US20200393455A1 (en) * | 2019-05-21 | 2020-12-17 | Regeneron Pharmaceuticals, Inc. | Methods for identifying and quantitating host cell protein |
| TW202140553A (zh) | 2020-01-13 | 2021-11-01 | 美商威特拉公司 | C5ar1抗體分子及其用途 |
| EP4126045A4 (en) * | 2020-03-31 | 2024-04-10 | Medimmune Llc | STABILIZED IGG4 ANTIBODIES AND USES THEREOF |
| JP2024502863A (ja) | 2021-01-13 | 2024-01-23 | ビステラ， インコーポレイテッド | ヒト化補体５ａ受容体１抗体及びその使用方法 |
| TW202306985A (zh) | 2021-07-12 | 2023-02-16 | 美商建南德克公司 | 降低抗體－脂酶結合之結構 |
| WO2023168352A1 (en) | 2022-03-03 | 2023-09-07 | Yale University | Humanized 3e10 antibodies, variants, and antigen binding fragments thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009307728B2 (en) * | 2008-10-20 | 2014-12-11 | Abbvie Inc. | Antibodies that bind to IL-18 and methods of purifying the same |
| PT2506871T (pt) | 2009-11-30 | 2016-11-07 | Janssen Biotech Inc | Mutantes de fc de anticorpos com funções efetoras inutilizadas |
| GB201014033D0 (en) * | 2010-08-20 | 2010-10-06 | Ucb Pharma Sa | Biological products |
| GB201203051D0 (en) * | 2012-02-22 | 2012-04-04 | Ucb Pharma Sa | Biological products |
| GB201203071D0 (en) * | 2012-02-22 | 2012-04-04 | Ucb Pharma Sa | Biological products |
| PL3044323T3 (pl) | 2013-09-13 | 2022-06-27 | F.Hoffmann-La Roche Ag | Sposoby wykrywania i ilościowego oznaczania białka komórki gospodarza w liniach komórkowych |
| NZ756750A (en) * | 2013-09-13 | 2022-05-27 | Genentech Inc | Methods and compositions comprising purified recombinant polypeptides |
| TW201628649A (zh) | 2014-10-09 | 2016-08-16 | 再生元醫藥公司 | 減少醫藥調配物中微可見顆粒之方法 |
-
2017
- 2017-10-03 MX MX2019003890A patent/MX2019003890A/es unknown
- 2017-10-03 KR KR1020197010590A patent/KR20190057083A/ko active IP Right Grant
- 2017-10-03 JP JP2019518304A patent/JP7471819B2/ja active Active
- 2017-10-03 AU AU2017338291A patent/AU2017338291A1/en not_active Abandoned
- 2017-10-03 CA CA3037264A patent/CA3037264A1/en not_active Abandoned
- 2017-10-03 CN CN201780061885.8A patent/CN109790216A/zh active Pending
- 2017-10-03 WO PCT/EP2017/075038 patent/WO2018065389A1/en unknown
- 2017-10-03 EP EP17787118.3A patent/EP3523329A1/en active Pending
- 2017-10-03 SG SG11201901468SA patent/SG11201901468SA/en unknown
- 2017-10-03 TW TW106134267A patent/TW201829453A/zh unknown
- 2017-10-03 RU RU2019106819A patent/RU2771330C2/ru active
- 2017-10-03 BR BR112019004938A patent/BR112019004938A2/pt not_active Application Discontinuation
- 2017-10-03 US US16/339,027 patent/US11254753B2/en active Active
-
2019
- 2019-04-01 IL IL265748A patent/IL265748A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2771330C2 (ru) | 2022-04-29 |
| WO2018065389A1 (en) | 2018-04-12 |
| MX2019003890A (es) | 2019-08-12 |
| JP2019532957A (ja) | 2019-11-14 |
| US20190225708A1 (en) | 2019-07-25 |
| US11254753B2 (en) | 2022-02-22 |
| BR112019004938A2 (pt) | 2019-06-25 |
| IL265748A (en) | 2019-06-30 |
| RU2019106819A (ru) | 2020-11-06 |
| RU2019106819A3 (zh) | 2021-06-04 |
| CN109790216A (zh) | 2019-05-21 |
| TW201829453A (zh) | 2018-08-16 |
| CA3037264A1 (en) | 2018-04-12 |
| JP7471819B2 (ja) | 2024-04-22 |
| KR20190057083A (ko) | 2019-05-27 |
| AU2017338291A1 (en) | 2019-03-14 |
| EP3523329A1 (en) | 2019-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201901468SA (en) | Antibodies with reduced binding to process impurities | |
| SG11201811003PA (en) | Anti-pd-l1 antibodies and uses thereof | |
| SG11201900746RA (en) | Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions | |
| SG11201908820VA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
| SG11201810933QA (en) | Anti-c5 antibodies and uses thereof | |
| SG11201805422WA (en) | Multivalent and multispecific ox40-binding fusion proteins | |
| SG11201910027YA (en) | Bispecific antibody against ox40 and ctla-4 | |
| SG11201907754RA (en) | Anti-phf-tau antibodies and uses thereof | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201809879WA (en) | Novel antibodies specifically binding to zika virus epitopes and uses thereof | |
| SG11201809331RA (en) | Antibodies recognizing tau | |
| SG11201403106SA (en) | Anti-phf-tau antibodies and their uses | |
| SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
| SG11201910134SA (en) | Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
| SG11201910066QA (en) | Antibodies recognizing tau | |
| SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
| SG11201408780XA (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
| SG11201806121PA (en) | Ror2 antibody compositions and related methods | |
| SG11201900744SA (en) | Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them | |
| SG11201907927SA (en) | Binding molecules that specifically bind to tau | |
| SG11201407800SA (en) | Selective binding of biological targets to solid phase ureides | |
| SG11201901673SA (en) | Imidazole derivatives and their use in the treatment of autoimmune or inflammatory diseases or cancers | |
| SG11201809793UA (en) | Tl1a antibodies and uses thereof | |
| SG11201408037SA (en) | Humanized anti-trka antibodies with amino acid substitutions | |
| SG11201903602RA (en) | Use of beta-catenin as a biomarker for treating cancers using anti-dkk-1 antibody |